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ABSTRACT
Background Understanding neutrophil heterogeneity 
and its relationship to disease progression has become a 
recent focus of cancer research. Indeed, several studies 
have identified neutrophil subpopulations associated with 
protumoral or antitumoral functions. However, this work 
has been hindered by a lack of widely accepted markers 
with which to define neutrophil subpopulations.
Methods To identify markers of neutrophil heterogeneity 
in cancer, we used single- cell cytometry by time- of- flight 
(CyTOF) coupled with high- dimensional analysis on blood 
samples from treatment- naïve patients with melanoma.
Results Our efforts allowed us to identify seven blood 
neutrophil clusters, including two previously identified 
individual populations. Interrogation of these neutrophil 
subpopulations revealed a positive trend between specific 
clusters and disease stage. Finally, we recapitulated these 
seven blood neutrophil populations via flow cytometry 
and found that they exhibited diverse capacities for 
phagocytosis and reactive oxygen species production in 
vitro.
Conclusions Our data provide a refined consensus on 
neutrophil heterogeneity markers, enabling a prospective 
functional evaluation in patients with solid tumors.
INTRODUCTION
Neutrophils are bone marrow (BM)- derived 
myeloid cells that play pivotal roles in anti-
cancer immunity.1 Neutrophils are produced 
at a rate of 1011 per day2 3 and comprise 
50%–70% of blood leukocytes. Due to this 
rapid turnover in the body, neutrophils have 
traditionally been viewed as a homogeneous 
population. However, recent work has shown 
that they exhibit a longer life cycle than previ-
ously thought,4 reviving interest in the possi-
bility of distinct neutrophil populations.3 5
Spurred on by such findings, several 
groups have since identified and charac-
terized several neutrophil subpopulations. 
For example, use of density gradient sepa-
ration has uncovered low- density neutrophil 
(LDN) and high- density neutrophil (HDN) 
populations, each with opposing actions in 
immune regulation and cancer progression.6 
Marini and coauthors employed flow cytom-
etry to show that CD10+ and CD10− neutro-
phils represent populations with opposing 
effects on T- cell proliferation.7 Pillay and 
colleagues identified three neutrophil 
subpopulations, based on their differential 
expression of CD16 and CD62L, with each 
exhibiting specific maturation and activa-
tion statuses.8 CD45RA, CD63, and CD11b 
also indicate activation statuses in certain 
neutrophil subsets.9 10 Singhal and collabo-
rators isolated a CD14+ neutrophil subpop-
ulation with antitumor functions, including 
enhancement of effector T cell- based 
production of interferon- g and granzyme B.11 
Evrard and colleagues have demonstrated a 
CD15+CD49+CD101− neutrophil precursor 
(preNeu).12 Our group has identified a 
CD117+CD66b+CD38+ human neutrophil 
progenitor (hNeP), which was also found in 
the blood of tumor- bearing animals.13 Addi-
tional work in this area is summarized in 
two excellent review articles.14 15 Neverthe-
less, a lack of widely accepted subpopulation 
markers has hindered our understanding 
of neutrophil heterogeneity. Indeed, the 
neutrophil subpopulations thus far described 
likely represent intersecting populations. For 
example, flow cytometry analysis suggests that 
CD10+ and CD10− neutrophil subpopulations 
are fractionated into both LDN and HDN 
layers.7 Furthermore, the CD10+ expression 
demonstrated by Marini et al7 is shared by the 
CD16bright subpopulation reported by Pillay 
et al.8 Specific CD14+ neutrophils present a 
CD10− phenotype,11 suggesting this subpop-
ulation overlaps with the CD10− neutrophil 
population.7 The CD14+ neutrophil subpop-
ulation also present a CD49d+ phenotype, 
2 Zhu YP, et al. J Immunother Cancer 2020;8:e000473. doi:10.1136/jitc-2019-000473
Open access 
indicating that it overlaps with the CD49d+ preNeu 
demonstrated by Evrard et al,12 as well as a CD49d+C-
D62Llo neutrophil subpopulation (‘aged neutrophil’) 
reported by Casanova- Acebes et al.16 To determine the 
extent to which previously reported neutrophil subpopu-
lations intersect, high- dimensional analysis of neutrophil 
heterogeneity on a single- cell basis is imperative.
We and others have employed high- dimensional 
approaches such as single- cell cytometry by time- of- flight 
(CyTOF) and single- cell RNA sequencing (scRNA- seq) 
to address neutrophil heterogeneity. These endeavors 
demonstrate that the neutrophil lineage comprises a 
heterogeneous pool in mouse and human BM.12 13 Addi-
tionally, scRNA- seq analyses reveal six neutrophil clusters 
with distinct transcriptional signatures in human lung 
tumors, but the surface markers needed to classify these 
populations were not identified.17 Interestingly, work in 
this field has also suggested differential involvement of 
neutrophil subpopulations in cancer.18 19 Thus, the devel-
opment of consensus neutrophil markers is required for 
improving our understanding of neutrophil biology and 
its relationship to disease progression.
Here, we use a CyTOF panel of the most commonly used 
surface markers of neutrophil maturation, activation, 
and function to comprehensively investigate neutrophil 
heterogeneity in whole blood (WB) from treatment- naïve 
patients with melanoma. High- dimensional analysis of 
this dataset revealed seven neutrophil subpopulations 
associated with disease stage and which are reproduc-
ible during manual gating in flow cytometry. Finally, we 
found that these seven neutrophil subpopulations harbor 
distinctive functions, demonstrated by their differential 
capacities for phagocytosis and reactive oxygen species 
(ROS) production.
METHODS
Melanoma patient blood collection
Blood samples from patients with melanoma who were 
treatment- naïve after surgical resection were collected in 
EDTA- coated tubes by the Biospecimen Repository Core 
Facility at the University of Kansas Cancer Center and 
delivered to La Jolla Institute for Immunology (LJI) via 
overnight shipping. Concurrently, blood from healthy 
donors was collected in EDTA- coated tubes at LJI. To 
ensure uniform treatment between control and experi-
mental materials, all healthy donor blood samples were 
stored at 4°C overnight and then processed the next 
morning.
Cell suspension from human WB
WB was subject to red blood cell (RBC) lysis (RBC lysis 
buffer, eBiosciences) twice at room temperature (RT) 
for 10 min. Cells were then washed with staining buffer 
(Dulbecco’s phosphate- buffered saline+1% human 
serum+0.1% sodium azide+2 mM EDTA) and filtered 
through a 70 µm strainer. Cells were pelleted by centrif-
ugation and suspensions were prepared with gentle 
pipetting to reach final concentration of 3×106 cells per 
100 µL buffer.
Mass cytometry antibodies
Metal- conjugated antibodies were purchased directly 
from Fluidigm for available targets. For all other targets, 
purified antibodies were purchased as described before.20 
Antibody conjugations were prepared using the Maxpar 
Antibody Labeling Kit (Fluidigm) according to the 
manufacturer’s recommendations. Afterwards, Maxpar- 
conjugated antibodies were stored in phosphate- buffered 
saline- based antibody stabilization solution (Candor 
Biosciences) supplemented with 0.05% sodium azide at 
4°C. All antibodies were titrated before use.
Mass cytometry (CyTOF)
CyTOF was performed following previously described 
protocols.20 For viability staining, cells were washed in 
phosphate- buffered saline and stained with Cisplatin 
(Fluidigm) at a final concentration of 5 µM. Prior to 
surface staining, RBC- lysed WB cells were resuspended in 
staining buffer for 15 min at RT to block Fc receptors. The 
surface antibody cocktail listed in table 1 was added into 
cell suspensions for 1 hour at 4°C. The cells were then 
washed with staining buffer and fixed with 1.6% para-
formaldehyde (Thermo Fisher) for 15 min at RT. After-
wards, 1 mL of intercalation solution for each sample was 
prepared by adding Cell- ID Intercalator- Ir (Fluidigm) 
into Maxpar Fix and Perm Buffer (Fluidigm) to a final 
concentration of 125 nM (a 1000× dilution of the 125 µM 
stock solution) and vortex to mix. After fixation, the cells 
were resuspended with the intercalation solution and 
incubated overnight at 4°C. Cells were then washed in 
staining buffer and then with subsequent washes in Cell 
Acquisition Solution (CAS) (Fluidigm) to remove buffer 
salts. Next, the cells were resuspended in CAS with a 1:10 
dilution of EQ Four Element Calibration beads (Flui-
digm) and filtered through a 35 µm nylon mesh filter cap 
(Corning, Falcon). Samples were analyzed on a Helios 
2 CyTOF Mass Cytometer (Fluidigm) equipped with a 
Super Sampler (Victorian Airship & Scientific Apparatus) 
at an event rate ≤500 events/s. Mass cytometry data files 
were normalized using the bead- based Normalizer21 and 
were analyzed using Cytobank analysis software (https://
www. cytobank. org/). For analysis of mass cytometry data 
with a self- organizing map (FlowSOM) in Cytobank, hier-
archical clustering was used to determine seven metaclus-
ters based on median marker expression (after arcsinh 
transformation with cofactor equal to 5) from the visu-
alization of t- distributed stochastic neighbor embedding 
(viSNE) results.
Flow cytometry and cell sorting
All fluorescence- activated cell sorting (FACS) staining was 
performed in staining buffer at 4°C. Cells were filtered 
through sterile, 70 µm cell strainers to obtain single- 
cell suspensions (30 000 cells per µL for flow cytometry 
analysis, 0.5–2×107 cells per mL for sorting). Prior to 
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surface staining, RBC- lysed WB cells were resuspended 
in staining buffer to block Fc receptors for 15 min at 
RT. Surface staining was performed for 30 min in a final 
volume of 500 uL for FACS sorts and 100 µL for standard 
flow cytometry. Cells were washed twice in at least 200 µL 
FACS buffer before acquisition. FACS was performed via 
an Aria II and Aria- Fusion (BD Biosciences) and conven-
tional flow cytometry via an LSRII and LSR Fortessa (BD 
Biosciences). All flow cytometry was performed on live 
cells. Percentages of CD45+ immune cells were calculated 
by forward and side scatter and viability analyses of live 
cells. All analyses and sorts were repeated at least three 
times, and the purity of each sorted fraction was deter-
mined visually and by FACS reanalysis of surface markers. 
Data were analyzed using FlowJo software V.10.5.
Phagocytosis
Phagocytic capacities of neutrophils were assessed with a 
Phagocytosis Assay Kit (Red Zymosan) (Abcam) following the 
manufacturer's protocol. RBC- lysed WB cells were diluted to 
a concentration of 3×106 cells in 1 mL buffer and incubated 
with 5 µL of zymosan slurry per sample at 37°C and 5% CO2 
for 2.5 hours. Afterwards, the samples were centrifuged for 
5 min at 400×g and then stained with 100 µL antibody cock-
tail for flow cytometry- based detection of phagocytosis of red 
zymosan particles by neutrophils.
Cellular ROS detection
ROS production by neutrophils was detected with a 
Cellular ROS Detection Assay Kit (Abcam) following 
the manufacturer's manual. The RBC- lysed WB cells 
were diluted to the concentration of 3×105 cells in 100 
mL buffer. Pretreatment with ROS inhibitor (N- acetyl- L- 
cysteine) was carried out for the negative control group 
at 37°C, 5% CO2 for 30 min. ROS detection antibody then 
added into the antibody cocktail for flow cytometry- based 
detection of neutrophil ROS production. ROS inducer 
(pyocyanin) was added to all groups and incubated for 30 
min prior to acquisition on the cytometer.
Quantification and statistical analyses
Data for all experiments were analyzed with Prism soft-
ware (GraphPad). For figure 1, linear regression and 
Pearson correlation coefficients were used to determine 
the correlation between neutrophil cluster frequencies 
with melanoma stages. Differences between groups were 
determined via ordinary one- way analysis of variance 
(ANOVA) and Tukey’s multiple comparison tests with 
a single pooled variance. For figure 2, paired Student’s 
t- tests were used to compare the differences between 
healthy patients and patients with melanoma. For 
figure 3B and E,F and online supplementary figure 7A,C–
E, differences between groups were determined by using 
Table 1 Cytometry by time- of- flight antibody panel
Leukocyte lineage Maturation Heterogeneity (function)
Isotope Metal Specificity Isotope Metal Specificity Isotope Metal Specificity
89 Y CD45 146 Nd CD64 153 Eu CD14
113 In CD3 151 Eu CD49d 161 Dy Arg1
113 In CD127 154 Sm CD117 168 Er CD304 
(Nrp1)
115 In CD41 156 Gd CD10 171 Yb HLA- -
A/B/C
115 In CD235a 158 Gd CD101 174 Yb HLA- DR
141 Pr CD11c 165 Ho CD16 Heterogeneity (migration)
143 Nd CD123 166 Er CD34 Isotope Metal Specificity
143 Nd CD203c 167 Er CD38 147 Sm CD182 
(CXCR2)
144 Nd CD19 172 Yb CD15 159 Tb CD197 
(CCR7)
148 Nd CD11b Heterogeneity (adhesion/activation) 175 Lu CD184 
(CXCR4)
152 Sm CD66b Isotope Metal Specificity Proliferation
163 Dy CD86 142 Nd CD11a (LFA-1) Isotope Metal Specificity
164 Dy Siglec 8 145 Nd CD62L 127 I IdU
169 Tm CD33 149 Sm CD48 162 Dy CD71
176 Yb CD56 155 Gd CD45RA       
Heterogeneity (other) 170 Er CD35       
Isotope Metal Specificity             
160 Gd CD79b             
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ordinary one- way ANOVA and Tukey’s multiple compar-
ison tests with a single pooled variance. For figure 3C 
and online supplementary figure 7B and F, ordinary 
two- way ANOVA and Sidak’s multiple comparisons tests 
with individual variances computed for each comparison 
were performed to compare the +zymosan and −zymosan 
groups. Error bars indicate means±SD. P values were 
calculated by two- tailed comparisons with 95% CIs and 
shown in American Psychological Association (APA) style.
RESULTS
CyTOF reveals seven neutrophil clusters in blood from 
patients with melanoma
In order to identify novel blood neutrophil populations, 
we used CyTOF mass cytometry to analyze RBC- lysed, 
fresh blood samples from a cohort of 21 patients with 
melanoma (table 2). At the time of sample collection, 
these patients were recently diagnosed, had not received 
any treatment for their condition (treatment- naïve), 
Figure 1 Neutrophil heterogeneity in patients with melanoma correlates with disease stage. (A) Pie charts show mean 
percentages for each FlowSOM cluster (hNeP and Cneut1–6) in total blood neutrophils of patients grouped by melanoma stage. 
Only patients with a melanoma stage diagnosis shown in table 2 were used for this analysis. The numbers of subjects in each 
melanoma stage are indicated on the graph. (B) Line regression analysis shown in dot plot depicting correlations between 
neutrophil cluster frequency and melanoma stage. Each dot represents one patient. Pearson analysis results are shown for each 
cluster. P values were calculated based on two- tailed comparisons with 95% CIs and shown in APA style. (C) Bar graph shows 
the mean percentage of each cluster in patient groups A–D. All patients were used for this analysis, regardless of whether or not 
they received a melanoma stage diagnosis (table 2). The numbers of subjects in each group are indicated below each column. 
(D) Violin plots show the neutrophil cluster frequency in patient pools A–D. Quartiles and median values of each patient pool are 
indicated as dotted lines. All patients were used for this analysis regardless of whether or not they received a melanoma stage 
diagnosis (table 2). Differences between groups were determined by using ordinary one- way analysis of variance and Tukey’s 
multiple comparison test with a single pooled variance. Error bars indicate mean±SD. P values were calculated based on two- 
tailed comparisons with 95% CIs and shown in APA style. (E) Bar graph shows the percentage of patients at different melanoma 
stages (table 2) in patient groups –D. All the patients were used for this analysis regardless of whether or not they received a 
melanoma stage diagnosis (table 2). The numbers of patients in each pool are indicated below each column. APA' American 
Psychological Association; FlowSOM, analysis of mass cytometry data with a self- organizing map; hNeP, human neutrophil 
progenitor; N/A, missing diagnosis information of patients.
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and ranged from 24 to 82 years of age, with a median 
age of 69 years (table 2). After processing, samples were 
subjected to a CyTOF antibody panel that simultane-
ously measured the expression of 40 neutrophil surface 
markers (table 1). Leukocyte lineage markers (table 1) 
were used to perform viSNE- automated analysis to study 
live CD45+ single cells in blood (online supplementary 
figure 1A). Neutrophils (CD66b+ cell- enriched cluster) 
were distinguishable from all other leukocytes using this 
strategy (online supplementary figure 1B).
We focused on the CD66b+ cell- enriched cluster to 
analyze the heterogeneity of neutrophils across all 
patient samples. Our results demonstrate that these 
samples contained a CD117+CD66b+, hNeP population 
(figure 4A), which we have formerly identified.13 In addi-
tion, FlowSOM analyses22 revealed another six neutrophil 
clusters (termed Cneut1 through Cneut6, figure 4B), 
each with distinct surface marker profiles (figure 4C). 
Two randomly selected healthy donors’ blood were used 
as a control group to identify bona fide blood neutrophil 
populations (online supplementary figure 2A). Compared 
with healthy donor blood neutrophils, neutrophils from 
patients with melanoma displayed higher heteroge-
neity and the frequency of the largest neutrophil cluster 
(Cneut2) decreased from >95% in healthy donors to 
<90% in patients with melanoma (online supplementary 
figure 2B). The marker profile of Cneut2 in healthy blood 
was not significantly different from Cneut2 in patients 
with melanoma (online supplementary figure 2C). As 
maturity markers are commonly used to distinguish circu-
lating neutrophil subpopulations in cancer,12 23 we next 
quantified expression of these markers in the Cneut1- 
Cneut6- clustered neutrophils. We found that cluster 
Cneut2 expresses high levels of CD101, CD10, and CD16 
Figure 2 Flow cytometry replicates the seven neutrophil subpopulations. (A) CD66b+ blood neutrophils were manually 
selected and subjected to sequential gating to identify the neutrophil subpopulations with CyTOF. Scales are shown in arcsinh 
transformation with cofactor equal to 5. (B) The gating strategy from (A) was validated by flow cytometry in treatment- naïve 
patients with melanoma. Scales are shown in biexponential scale. (C) Flow cytometry analysis of healthy donor’s blood 
neutrophils with the gating strategy from (A). Scales are shown in biexponential scale. (D) Flow cytometry analysis of the 
frequency of each manually gated neutrophil subpopulation in total blood neutrophils. Five healthy donors (age 23–46, two 
women and three men) and five treatment- naïve patients with melanoma (aged 59–79 years, two women and three men) were 
analyzed. Each dot represents the result of one patient. Paired t- tests were used to compare the differences between healthy 
patients and patients with melanoma. Error bars indicate mean±SD. P values were calculated based on two- tailed comparisons 
with 95% CIs and shown in APA style. CyTOF, cytometry by time- of- flight; hNeP, human neutrophil progenitor.
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compared with the other clusters, indicating its enrich-
ment for terminally differentiated, mature neutrophils 
(figure 4C,D).7 Furthermore, CD10lo clusters (Cneut1 
and Cneut3- Cneut6) express reduced levels of CD101, 
highlighting their immaturity12 when compared with the 
Cneut2 cluster (figure 4D). The Cneut1, Cneut3, and 
Cneut6- clustered neutrophils express progenitor markers 
(CD34 and CD117) at a lower level than hNeP, but at a 
higher level than other clusters (figure 4D and online 
supplementary figure 3A). In the Cneut5 cluster, expres-
sion of CD34 and CD117 was diminished, compared 
with Cneut1, Cneut3, and Cneut6 (online supplemen-
tary figure 3A). In contrast, CD10 and CD16 levels were 
higher in the Cneut5 cluster, compared with Cneut3 and 
Figure 3 Seven neutrophil subpopulations harbor diverse phagocytic and ROS- producing capacities. Three randomly selected 
melanoma- naïve patients (ages 59, 77 and 79; one woman and two men) were analyzed with flow cytometry. (A–C) RBC- lysed 
blood samples were incubated with prelabeled zymosan particles for 2.5 hours. Afterwards, the cells were harvested and 
stained with the flow cytometry panels described in figure 2 and online supplementary figure 6C. Each neutrophil subpopulation 
was gated to evaluate its uptake of zymosan particles. (A) The zymosan- positive cells are shown in red; the zymosan- negative 
cells are shown in blue. The no- zymosan group (−zymosan) is shown in the bottom panels as the control group. (B) Percentage 
of the zymosan- positive cells (red dots in A) in each gated neutrophil subpopulation. Error bars indicate mean with SD. (C) gMFI 
of zymosan in each gated neutrophil subpopulation. Error bars indicate mean with SD. (D) Seven neutrophil subpopulations’ 
ability to produce ROS is determined by flow cytometry. RBC- lysed blood samples were split into three groups and incubated 
with −sti, +sti, or sti+ROSi. Afterwards, each neutrophil subpopulation was gated for evaluation of ROS+ cells. Histogram plots 
show the gated neutrophil subpopulations in each group: −sti is shown in black; +sti is shown in red; +sti+ROSi is shown in 
blue. (E) Percentage of the ROS+ cells in each gated neutrophil subpopulation from the +sti group. Error bars indicate mean 
with SD. (F) ROS gMFI FC of each gated neutrophil subpopulation from the +sti group to the −sti group. Statistics: (B,E,F) 
differences between groups were determined by using ordinary one- way ANOVA and Tukey’s multiple comparison test with a 
single pooled variance. (C) Ordinary two- way ANOVA and Sidak’s multiple comparison test with individual variances computed 
for each comparison were performed to compare between +zymosan and −zymosan groups. Error bars indicate mean±SD. P 
values were calculated based on two- tailed comparisons with 95% CIs and shown in APA style. APA, American Psychological 
Association; ANOVA, analysis of variance; FC, fold change; gMFI, geometric mean fluorescence intensity; hNeP, human 
neutrophil progenitor; RBC, red blood cell; ROS, reactive oxygen species; ROSi, reactive oxygen species inhibitor; SSC- A, −sti, 
no stimulation; +sti, ROS inducer (pyocyanin) alone.
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Cneut6, intimating that this cluster denotes immature 
neutrophils (figure 4D). Moreover, Cneut3 and Cneut6 
both express CD101−CD49d+, which suggests these clus-
ters belong to the preNeu population.12
We further characterized these clusters by comparing 
functional markers previously used to evaluate neutro-
phil populations (figure 4E). In agreement with the 
initial findings in figure 4C, Cneut2 expressed the highest 
CXCR2 levels, confirming its maturation status. Interest-
ingly, Cneut3 and Cneut6, which are both identified as 
belonging to the CD101−CD49d+ preNeu pool, exhib-
ited differential levels of CD45RA and CD14. CD45RA 
was expressed only by Cneut3, whereas CD14 was exclu-
sively expressed by Cneut6. Additionally, Cneut3 exhib-
ited higher CXCR4 levels, compared with cluster Cneut6, 
which suggests Cneut3 represents a previously reported 
senescent (CXCR4+CD49d+CD62Llo) neutrophil 
population (online supplementary figure 3B).16 Finally, 
Cneut1 and Cneut6 expressed low amounts of CD16, 
compared with Cneut2 (figure 4D), and stained posi-
tive for CD62L (figure 4E), suggesting these cells are the 
CD16dimCD62Lbright band cells that have been described 
previously.8 Overall, our approach was able to recapitu-
late both novel and established neutrophil populations 
from the peripheral blood of patients with melanoma.
Neutrophil heterogeneity correlates with melanoma stage
Based on the aforementioned results, we sought to 
determine the frequency of each neutrophil cluster in 
our patient samples. We did not observe enrichment 
of specific neutrophil clusters related to patient demo-
graphics, such as age and sex, or tumor characteris-
tics, such as the anatomical site or ulceration status. No 
significant correlations were observed between cluster 
frequency changes and these patient demographics 
described in table 2. However, the overall frequency of 
precursors/immature neutrophils (hNeP, Cneut1, and 
Cneut3- Cneut5) increased up to fourfold with disease 
prognosis (figure 1A and online supplementary figure 
4A,B), whereas positive correlation was observed between 
Cneut2’s percentage of total neutrophils with melanoma 
stage (Pearson r=0.5473, p=0.023) determined by regres-
sion analysis (figure 1B). Thus, we hypothesized that 
different patterns of neutrophil heterogeneity demon-
strated by cluster frequencies are predictive of disease 
stage. To test this hypothesis, we categorized patients into 
four different groups (A–D) based on these patterns, as 
analyzed by viSNE (figure 1C and online supplementary 
figures 4C,D). From this analysis, we determined that 
patients in group C have the highest hNeP, Cneut1 and 
Cneut3 frequencies. Patients included in group D have 
the highest Cneut4 and Cneut5 frequencies (figure 1D). 
The frequency of Cneut2 progressively decreases from 
patient groups A–D. We next investigated the melanoma 
stage of the patients in these four groups (figure 1E). 
Interestingly, patients in group A were all diagnosed with 
early- stage cancer, whereas groups C and D contained 
the highest percentages of stage III and stage IV patients. 
These results suggest that specific patterns of neutrophil 
heterogeneity are associated with melanoma progression 
and may assist in patient grouping and diagnosis.
Flow cytometry recaptures the seven neutrophil 
subpopulations in the blood of patients with melanoma
We then asked if the markers highlighted in our in silico 
analysis could be used to devise a manual gating strategy 
for replicating the seven neutrophil clusters identified by 
CyTOF (figure 2A and online supplementary figure 5). 
Thus, we first used manual gating to isolate total neutro-
phils from the CyTOF data. These cells overlapped with 
90% of our automated CD66b+ cell- enriched cluster 
by backgating (online supplementary figure 5). After 
applying a manual gate for CD66+ neutrophils, we reca-
pitulated the seven subpopulations, by examining the 
expression patterns of CD117, CD79b, CD45RA, CD16, 
Table 2 Patient demographics and tumor characteristics
Characteristics
Age (years)
  Median (range) 69 (24–82)
Sex, n (%)
  Male 12 (57.1)
  Female 9 (42.9)
Primary tumor thickness (mm)
  n (range) 13 (0.4–16)
  0–1.00, n (%) 4 (19)
  1.00–4.00, n (%) 6 (28.6)
  >4.00, n (%) 3 (14.3)
  Missing, n (%) 8 (38.1)
Primary tumor ulceration status, n (%)
  Absent 9 (42.9)
  Present 4 (19)
  Missing 8 (38.1)
Primary tumor anatomical site, n (%)
  Arms/legs 5 (23.8)
  Torso 5 (23.8)
  Head/neck 7 (33.3)
  Missing 4 (19)
Primary tumor mitosis, n (%)
  Absent 5 (23.8)
  Present 7 (33.3)
  Missing 9 (42.9)
AJCC Cancer Staging Manual stage at pathological 
diagnosis, n (%)
  Stage I 8 (38.1)
  Stage II 4 (19)
  Stage III/IV 5 (23.8)
  Missing 4 (19)
AJCC, American Joint Committee on Cancer.
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CD49d, CD101, and CD10. To verify whether manually 
gated populations mirror automated clusters, we vali-
dated this gating strategy by (1) back- gating the manu-
ally gated subpopulations to the automated viSNE map 
and (2) back- gating automated clusters to the manual 
gates (online supplementary figure 6AB). Both methods 
confirmed that our manual gating strategy is able to 
successfully isolate the CyTOF- identified hNeP and 
Cneut1–Cneut6 neutrophil clusters.
Next, we further validated this manual gating strategy 
(online supplementary figure 4 and figure 2A) via 
flow cytometry (online supplementary figure 6C and 
Figure 4 CyTOF- based analysis of blood from patients with melanoma reveals seven automated neutrophil clusters. The 
blood neutrophils (the CD66b+ automated cluster from online supplementary figure 1B) from treatment- naïve patients with 
melanoma were subjected to automated analysis. (A) Mean intensities of CD117 and CD66b expression are shown on viSNE 
map as spectrum colored dots (low in blue, high in red). hNeP was identified on the viSNE map based on the expression of 
CD117+CD66b+. (B) FlowSOM analysis of the viSNE results revealed seven automated clusters. (C) Heatmap shows the mean 
intensity of each marker in the six unidentified automated clusters on a global scale. (D) Dot plot shows the mean intensity 
of each maturity marker in the six unidentified automated clusters. Each dot represents the result of one patient. (E) Dot plot 
shows the mean intensity of each functional marker in the six unidentified automated clusters. Each dot represents the result of 
one patient. CyTOF, cytometry by time- of- flight; FlowSOM, analysis of mass cytometry data with a self- organizing map; hNeP, 
human neutrophil progenitor; viSNE, visualization of t- distributed stochastic neighbor embedding.
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figure 2B,C). To validate the utility of these findings as 
they relate to cancer, we investigated neutrophil hetero-
geneity in five healthy donors (age 23–46, two women, 
three men) and compared them to five additional 
treatment- naïve patients with melanoma (aged 59–79 
years, two women and three men). We observed that the 
Cneut2 population comprised >95% of total neutrophils 
in healthy donors, whereas the other populations (hNeP, 
Cneut1, Cneut3, Cneut4, Cneut5, and Cneut6) were 
rarely detected (figure 2C,D). Moreover, compared with 
healthy donors, these subpopulations (hNeP, Cneut1, 
Cneut3, Cneut4, Cneut5, and Cneut6) appeared more 
frequently in treatment- naïve patients with melanoma, 
which occupied >10% total neutrophils, as determined 
by flow cytometry. The frequencies of Cneut2, however, 
were reduced to <90% of total neutrophils in the blood 
of patients with melanoma. This result is consistent with 
the CyTOF results we observed in online supplementary 
figure 2 and prior findings showing that both immature 
neutrophils and preNeus are mobilized in cancer.24 25
Seven neutrophil subpopulations perform diverse immune 
functions
Afterwards, we sought to determine whether the seven 
neutrophil subpopulations we identified express unique 
immunological phenotypes. Phagocytosis and gener-
ation of ROS are two major functions of neutrophils 
in the immune system.26 Therefore, we evaluated the 
seven neutrophil subpopulations’ phagocytic and ROS- 
producing capacities.
The seven neutrophil subpopulations from three 
randomly selected patients with melanoma (age 59, 77, 
and 79 years, one woman and two men) were analyzed 
for their phagocytosis of prelabeled zymosan particles. 
Uptake of zymosan particles by neutrophil subpopula-
tions was then quantified by gating with flow cytometry 
(red in the zymosan- added (+zymosan) group, figure 3A 
top panels) and compared with the control (non- zymosan- 
added (−zymosan) group, figure 3A bottom panels). To 
determine each subpopulation’s phagocytic ability, we 
compared the zymosan- positive portion (Zym+Neuts) in 
each neutrophil subpopulation from the zymosan- added 
(+zymosan) group. Strikingly, each neutrophil subpop-
ulation performed phagocytosis at different levels of 
efficiency. Our results show that the hNeP and Cneut1 
populations display the highest phagocytic capacities 
(figure 3B,C). Indeed, the phagocytic abilities of hNeP 
and Cneut1 were comparable to, or higher than, those 
of monocytes collected from the same donors (online 
supplementary figure 7A,B). Moreover, the phagocytic 
capabilities of the other subpopulations were reduced 
by 3- fold to >20- fold (figure 3B,C). Despite the fact that 
Cneut2 and Cneut5 harbored a lower phagocytic capacity 
compared with hNeP and Cneut1, they were the most prev-
alent neutrophil subpopulations in the blood of patients 
with melanoma (figures 1 and 4). Therefore, the absolute 
numbers of Zym+ Cneut2 and Cneut5 cells still comprise 
the largest portion (about 50%) of all phagocytic (Zym+) 
neutrophils and about 25% of total phagocytic CD45+ 
leukocytes (online supplementary figure 7C,D).
Finally, we sought to determine the ability of neutrophil 
subpopulations to produce ROS. The seven neutrophil 
subpopulations from three additional randomly selected 
melanoma- naïve patients (age 59, 77, and 79, one woman 
and two men) were analyzed by flow cytometry. The 
ability of gated neutrophils to produce ROS was evalu-
ated in three experimental groups: no stimulation (−sti), 
ROS inducer (pyocyanin) alone (+sti), or ROS inducer 
plus ROS inhibitor (+sti+ROSi). We ascertained that 
all seven neutrophil subpopulations produced ROS on 
stimulation with pyocyanin and responded to the inhib-
itor (figure 3D). However, these cells significantly differ 
from one another in terms of their ability to produce 
ROS. For instance, the Cneut2 and Cneut5 subpopula-
tions displayed the highest percentage of ROS+ cells in 
the inducer alone (+sti) group (figure 3E). Meanwhile, 
populations Cneut4 and Cneut6 showed the lowest ROS- 
producing capacity of all the subpopulations, with levels 
comparable to those produced by monocytes (figure 3E 
and online supplementary figure 7E). To eliminate 
confounding by non- inducer- specific ROS production 
by each population during incubation, we compared 
the fold change (FC) of ROS gMFI in the inducer alone 
(+sti) group to the no- stimulation (−sti) group. The FC 
result agreed with our observation that the N2 has the 
highest ROS- producing capacity (figure 3F). Addition-
ally, we found that all subpopulations responded to the 
ROSi at different levels. In brief, pretreatment with ROSi 
blocked ROS production in Cneut2 by 85%, whereas the 
blocking efficacy reached only around 25% in Cneut4 
(online supplementary figure 7F). Together, our data 
indicate that the seven neutrophil subpopulations harbor 
different immunological capabilities.
DISCUSSION
Neutrophil heterogeneity has become an active 
research area, particularly with regard to cancer 
progression.18 Neutrophils carry out contrasting roles 
in cancer by either killing cancer cells (antitumoral 
functions) or promoting tumor growth (protumoral 
functions).18 Such observations have long suggested 
the existence of distinct neutrophil subpopula-
tions. Traditionally, neutrophil subtypes have been 
separated via gradient centrifugation methods and 
without use of surface marker characterization, partic-
ularly in cancer- related research.1 18 The advent of 
flow cytometry has revealed that neutrophils express 
a diverse set of surface antigen profiles.27 However, 
due to the limitations imposed by flow cytometry, 
researchers have had to arbitrarily select only a few 
surface markers to examine at any particular time. For 
example, studies in lung cancer research traditionally 
use one set of markers to identify their neutrophils 
of interest, whereas studies in infectious diseases use 
another set of markers; this is also the case for work 
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on the role of neutrophils in both hematopoiesis and 
angiogenesis.15 19 Consequently, neutrophil subpopu-
lations reported by different groups share individual 
features such as CD66b and/or CD15 but vary in regard 
to the assessment of other surface antigens. Thus, a 
lack of consensus markers for neutrophils and their 
functional subpopulations remains a challenge in the 
identification of disease- relevant subpopulations.
High- dimensional analysis of neutrophils at the 
single- cell level is needed to resolve issues associated 
with identifying neutrophil consensus markers. To 
meet this demand, we and others have used CyTOF to 
investigate novel neutrophil progenitors/precursors 
in BM.12 13 Zilionis and colleagues have reported a 
comprehensive analysis of myeloid cell heterogeneity 
via single- cell transcriptomics in non- small- cell lung 
cancer.17 This study found six blood neutrophil popu-
lations with unique gene signatures in these patients; 
a myeloid precursor- like population was also found 
but remained uncharacterized. However, the genes 
that encode surface markers were not discussed in this 
study, making it a challenge to compare these neutro-
phil and myeloid precursors to established neutrophil 
subpopulations.
Herein, we aimed to establish a paradigm for char-
acterizing neutrophil heterogeneity and correlating 
specific neutrophil subsets with cancer severity. As 
such, we designed a CyTOF panel to evaluate the 
expression of the most commonly used surface anti-
gens in neutrophil samples from patients with mela-
noma. We identified seven neutrophil clusters in the 
blood of treatment- naïve patients with melanoma 
by CyTOF and present evidence indicating that 
several previously identified neutrophil subpopula-
tions overlap with one another6 12 16 and/or repre-
sent a mixed pool.7 8 This study has also provided a 
flow cytometry gating strategy, based on our CyTOF 
work, to recapitulate these seven neutrophil subpop-
ulations. Our results show that these subpopulations 
display differing capacities to phagocytize debris and 
produce ROS. Interestingly, a decrease in the ability 
of T cells to both bind peptide- MHC dimers and 
respond to specific peptides is induced by myeloid 
cell- based production of ROS.28 Conversely, myeloid 
production of ROS has been shown to be indispens-
able for antigen- specific responsiveness in both CD4+ 
and CD8+ T cells.29 This controversial role of ROS in 
regulating T- cell activity could be partially explained 
by the dual role of ROS; at low to moderate concentra-
tions, ROS is beneficial for cell survival, whereas high 
levels of ROS can induce cell death.30 Therefore, the 
abilities of these seven neutrophil subpopulations to 
produce ROS suggests that they may carry out distinct 
roles in regulating T- cell responses in cancer. Inter-
estingly, our results show marked similarity between 
these subpopulations and previously reported neutro-
phil subtypes with immature developmental statuses. 
We hypothesize that the heterogeneity we observed in 
neutrophils derived from patients with cancer may be 
due to recruitment of preNeus and immature neutro-
phil populations from the BM to the circulation via 
cancer- related cytokines such as granulocyte colony- 
stimulating factor. Because the CyTOF panel used in 
this study is selective for human blood neutrophil and 
cancer markers, our results do not capture neutrophil 
heterogeneity across species, organs, and/or different 
diseases. Higher dimensions of heterogeneity within 
our reported subpopulations under such biolog-
ical conditions should be the focus of future work. 
Some rare neutrophil subpopulations, such as those 
expressing T cell receptor (TCR),31 could also be lost 
during our gating. Furthermore, we are unable to rule 
out the possibility of phenotypic switching between 
these seven subpopulations and thus consider this 
notion an interesting direction for follow- up.6 32
In summary, our analysis of neutrophil heteroge-
neity with CyTOF successfully demonstrated marked 
neutrophil heterogeneity patterns in each treatment- 
naïve patient sample, based on each cluster’s frequency 
as a proportion of total neutrophils. We identified 
groups of patients based on similarities between 
these neutrophil heterogeneity patterns. The patient 
groups displayed different melanoma stage categories, 
suggesting a link between neutrophil heterogeneity 
and disease, but further validation is needed. We have 
also shown that these automated clusters can be repro-
duced by manual gating in conventional flow cytom-
etry. Finally, we demonstrate that these neutrophil 
subpopulations exhibit significantly different capaci-
ties for phagocytosis and ROS production. Thus, we 
hypothesize these subpopulations play different roles 
in cancer initiation and/or progression.
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